Dr. Meeker is the Chairman, President & CEO of Rhythm Pharmaceutical, a biotechnology company focused on developing innovative therapies for rare genetic disorders of obesity. Dr. Meeker was formerly the President and CEO of Genzyme, a Sanofi company, a position he assumed when Genzyme merged with Sanofi in 2011. He was also a member of the Sanofi executive committee. He was most recently CEO of KSQ Therapeutics an early-stage functional genomics company. David is also the Chairman of the Board for Pharvaris.
In his career with Genzyme, Dr. Meeker held key positions of increasing responsibility beginning in the R&D organization and subsequently in operating roles, culminating in the position of Chief Operating Officer at the time of the merger. In his most recent role within Sanofi, he headed Sanofi-Genzyme, the specialty care unit with responsibility for Rare Diseases, MS, Oncology and Immunology franchises.
Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He completed his internal medicine training at Harvard’s Beth Israel Hospital and his pulmonary/critical care training at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.
Dr. Meeker is the Chairman of the Board of Trevi Therapeutics and a member of the board at Myokardia. He also serves on the boards of the Biomedical Science Careers Program, the Network for Excellence in Health Innovation, and the Dimock Center, a Boston-based community health center.